CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration

NEXT STORY
CorMedix Receives Encouraging FDA Feedback on Neutrolin® LOCK-IT-100 Data
PREV STORY
Inovalon Reaches Milestone and Achieves Integration With Epic
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Easton Pharmaceuticals Announces Key Management Addition With the Appointment of Dr. Daniel Bagi, M.D. to the Board of Directors; Provides Other Updates

TORONTO, ON, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Easton Pharmaceuticals (OTC:EAPH) announces the appointment ...

author_avatar
NASDAQ Market News

Argos Therapeutics to Participate in 2016 EORTC-AACR-NCI Symposium

DURHAM, N.C., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an ...

author_avatar
NASDAQ Market News

Quipt Adds 15,000 Active Patients With Closing of Strategic Acquisition Within a Metro Hub of Missouri

author_avatar
NASDAQ Market News